Taken together, our study suggests that GSCs may maintain ribosome biogenesis through upregulating WDR12; thus, targeting ribosome biogenesis via WDR12 represents a therapeutic index for GBM treatment. The gene discussed is WDR12; the disease is glioblastoma.